Business Wire

Pharnext Announces Acceptance of Late Breaking Abstract at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Del

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that new synergy data related to PXT864, the Company’s second lead PLEODRUG™ in development for the treatment of Alzheimer’s disease (AD), will be presented as a late breaking poster at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, on November 1-4, 2017, in Boston (US). In addition, Pharnext will present other data related to PXT864 as a poster at the same meeting.

Details are as follows:

Poster Session Theme : Clinical Trials Results - All day, November 1-2, 2017
Boston Park Plaza, Georgian Room (Mezzanine Level)

  • Poster #LBP32BIS (late breaking) : “Direct double-blind analysis arguing for synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in Human AD”, J. Touchon et al.
    Presenter : Mickaël Guedj, PhD, Chief Data Officer, Pharnext, France
  • Poster #P-40 : “Treatment with PXT864 Showed Stabilisation of Cognitive Disability in Mild Alzheimer’s Disease after 36 Weeks”, J. Touchon et al.
    Presenter : René Goedkoop, MD, Chief Medical Officer, Pharnext, France

PXT864 is a novel synergistic, fixed, low-dose combination of baclofen and acamprosate administered orally, twice-daily. PXT864 acts through a new mechanism of action that targets a metabolic imbalance in the brains of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), is also planned.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com

Contact information

Pharnext
René GoedKoop
Chief Medical Officer
medical@pharnext.com
+33 (0)1 41 09 22 30
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki
matthew@sternir.com
+1 212 362 1200
or
Financial Communication (France)
Actifin
Stéphane Ruiz
sruiz@actifin.fr
+33 (0)1 56 88 11 15
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Aurore Gangloff
pharnext@alizerp.com
+33 (0)1 44 54 36 64
or
Media Relations (U.S.)
RooneyPartners
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor AC LED Modules Pass 4kV Surge Testing23.5.2018 18:40Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, has demonstrated a 277V AC lighting module using its NanoDriver Series LED driver that complies with the industry standard 4kV surge testing. Prior to this, AC LED modules have been mainly used only in residential lighting applications due to the technology’s limited capability to meet the surge requirements for industrial and commercial applications. This demonstration module proves that it is possible to achieve a 277VAC module with high surge capability using Seoul Semiconductor’s NanoDriver Series LED driver. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523006267/en/ Seoul Semiconductor AC LED modules with Acrich technology demonstrate compliance at 4kV surge test. (Photo: Business Wire) Prior to Seoul Semiconductor’s recent product introduction, many LED fixture designers perceived AC LED technology as a low performance, low cost solution, assu

GCEL Releases G20 Nations Case Study Involving 90 Ministries, NGOs & IGOs Defining the Guidelines for the Digital Economy Era23.5.2018 18:34Pressemelding

GCEL, INSME, BVMW and CONFAPI executed a strategic agreement at the European Union Parliament to deploy the Digital Economy Platform (DEP) through GCEL’s HumaWealth Program that digitizes the USD 140 trillion B2B marketplace. These agreements will implement the newly released G20 Nations Case Study recommendations providing the roadmap to reduce annual domestic and international trade costs by USD 3.7 trillion, increase trade by USD 7.7 trillion, create a USD 1 trillion SME fund and generate 300 million manufacturing, agricultural and service industry jobs by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523006259/en/ GCEL, INSME, BVMW and CONFAPI executed a strategic agreement at the European Union Parliament to deploy the Digital Economy Platform in collaboration with the world's leading technology firms to digitize the USD 140 trillion B2B marketplace (Photo: Business Wire) The agreement was signed by Captain Sa

LTI Q4 USD Revenue Growth up 5.3% QoQ and 21.6% YoY; FY18 Revenues of USD1.13bn, up 16.7%; Digital Revenues Grow 42% in FY1823.5.2018 15:04Pressemelding

Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q4 FY18 and full year FY18 results today. Q4 FY 18 In US Dollars: Revenue at USD 309.0 million; growth of 5.3% QoQ and 21.6% YoY Constant Currency Revenue growth of 4.5% QoQ and 18.7% YoY In Indian Rupees: Revenue at Rs 20,012 million; growth at 6.2% QoQ and 19.3% YoY Net Income at Rs 2,894 million; Net Income growth at 2.3% QoQ and 13.7% YoY Full year FY18 In US Dollars: Revenue at USD 1,132.3 million; growth of 16.7% YoY Constant Currency Revenue growth of 14.7% YoY In Indian Rupees: Revenue at Rs 73,065 million; growth at 12.4% YoY Net Income at Rs 11,124 million; Net Income growth at 14.6% YoY “Our outstanding growth of 5.3% QoQ in Q4 is a result of a broad-based performance across all verticals. We have delivered an industry leading growth of 16.7% for the full financial year with digital revenues up 42% YoY. Our sustained investments in exponential technol

Zebra Medical Vision Announces CE Approval of its Seventh AI Imaging Algorithm - Mammography Lesion Detection23.5.2018 15:00Pressemelding

Zebra Medical Vision (http://zebra-med.com/) announces today the CE regulatory approval of its newest algorithm to be included in its growing Deep Learning Imaging Analytics platform. The algorithm, capable of detecting suspected malignant lesions in Mammography scans - is the latest addition to other automated tools announced in the past as part of it’s “All-In-One” AI1 business model, among them algorithms that automatically detect brain bleeds, vertebral fractures, coronary artery disease, osteoporosis and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005843/en/ Credit: Zebra Medical Vision According to the American Cancer Society, breast cancer makes up 25% of all new cancer diagnoses in women globally - with nearly 1.7 million women being diagnosed annually. Survival rates, though improving - vary worldwide. In countries with advanced care, the rate is 80 to 90 percent for those with a first-stage diagnosis

Korea's Government-Backed HOOXI Campaign Issues W Green Pay (WGP), First Blockchain Enabled Reward System for GHG Reduction by Individuals23.5.2018 13:00Pressemelding

W Green Pay (WGP), the blockchain from HOOXI, Korea's government-backed Greenhouse Gas (GHG) reduction campaign, is taking a different tack at encouraging individuals to reduce GHG. While GHG reduction initiatives have been around, HOOXI is the first to directly reward individuals for reducing GHG. HOOXI introduces the first blockchain to help enable the reward system and facilitate the on-going reward distribution to individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005643/en/ Youree Lee (third from left), CEO of W-Foundation, along with campaign ambassadors Korean idol group INFINITE members and Korean government officials, during the HOOXI Campaign Committee Inauguration Ceremony at The National Assembly of Republic of Korea on 26th April 2018. PHOTO: W-FOUNDATION W-Foundation, an international non-profit organization and a designated donation organization entitled by the Ministry of Strategy and Finance o

Nordson EFD Introduces New GV Series Gantry Fluid Dispensing Robot with Vision23.5.2018 12:04Pressemelding

Nordson EFD, a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, introduces the vision-guided GV Series automated fluid dispensing gantry robot. Specialized DispenseMotion™ software and an integrated CCD smart vision camera or simple pencil camera make the automated systems quick to set up and easy to program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005033/en/ The new GV Series gantry robot from Nordson EFD is ideal for precision fluid dispensing onto substrates that require large working envelopes with market-leading deposit placement repeatability. (Photo: Business Wire) The CCD camera converts pixels into digital values to deliver precise, high-quality images. The proprietary dispensing software confirms workpiece presence and placement and automatically adjusts as in-process variations occur. “With working envelopes that range from 400 mm to 800 mm and unlim